Trials / Unknown
UnknownNCT01311050
A Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer
A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 46 (estimated)
- Sponsor
- King Faisal Specialist Hospital & Research Center · Academic / Other
- Sex
- All
- Age
- 14 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination with Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer
Detailed description
A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination with Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab | Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab |
Timeline
- Start date
- 2009-01-01
- First posted
- 2011-03-09
- Last updated
- 2011-12-13
Locations
1 site across 1 country: Saudi Arabia
Source: ClinicalTrials.gov record NCT01311050. Inclusion in this directory is not an endorsement.